28% use internet, mobile apps as primary sources of health information

American consumers are becoming increasingly dependent on technology for self-care, care information and communication with providers, according to a UnitedHealthcare's 2017 Consumer Sentiment Survey.

The survey, which included the responses of 1,006 adults, provides insights into how consumers utilize technology in regard to their health. Findings include:

  • 28 percent of Americans use the internet or mobile apps as their primary source of information on specific health conditions, symptoms and diseases, an increase of 3 percent from last year.
  • 36 percent of millennials and 20 percent of baby boomers use the internet or mobile apps as their primary source of health information.
  • 45 percent of Americans prefer an in-person consultation with physicians, a 3 percent decrease from last year.
  • 32 percent of respondents using the internet of mobile apps to compare healthcare services.
  • 44 percent of millennials shop for healthcare services online.
  • 80 percent of Americans using the internet or mobile apps for comparison shopping reported the experience as “very helpful” or “somewhat helpful.”
  • 42 percent of Americans reported being “likely” to use telehealth services in the future; 46 percent said they were “unlikely.”
  • Respondents listed improving access to care as the biggest benefit to using telehealth, followed by convenience and cost.
""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.